Agree, the 33 news has been churning now for a while and the market is starting to react to the significance of having another big product entering the market for SGEN.
Since you are so kind to share faves you might want to look at one I've had the pleasure of a nice run up with - FLXN. There appears to be room to run. Who knows - the Sgen run may finally have it's legs after waiting years for the sustained uptrend. I'm not the trader Fs is (not knocking it - just afraid to chase the end run).
I got out of EXEL too early from my position under $1.50 but love seeing it succeed. I think EXEL, ISR and SGEN will all be bought out this year or next.
Sentiment: Strong Buy
I was going to look at EXCEL but haven't had the time. Love the strength in SGEN, and good to see biotech recovering in general. I just wish VSAR would wake up on heavy volume. That alone would make my year.
Rosetta-Your stocks are looking great today! I sold 1/2 my position in EXEL; right or wrong no one knows but a profit is a profit. If there is a dip next week in AQXP I will re-enter.
There is only 1 way for Baker to exit his position in SGEN and that is through a buyout. I own a few others of theirs and also some smaller names like ADVM and ISR, looking for pops in those soon. GL
Sentiment: Strong Buy
Me too. Nice move the last 5 days. I had to get back in AQXP and CHASE it. I sold too early but got back on the dip today and sold again. I will play it again next week. Most bios are on a run so will play until they settle down.
I think as important as PFS or OS with this aggressive disease is the quick time to blast clearance, CR/CRi which is accomplished usually by the 2nd treatment. The quick clearance and low 30 -60 day mortality rate will give a window of opportunity for oncologists to recommend and perform ASCT which may give some patients a chance at definitive cure. While not all elderly patients will be candidates for transplant it appears that the Cr/CRi rate with negative MRD compares very favorably with the SOC systemic chemotherapy that is given to AML patients that are fit enough to handle it. It would be a great advantage to avoid the systemic chemo as that is so taxing on the body. Getting these patients to transplant I believe is the goal.
While 50 patients is not a large sample size the data has been getting better since Dec., and these results are in some of the worst patients. Very old, prior treatments, aggressive disease charachteristics.
I'm excited as AML is double the patient population of HL, and if it moves into earlier treatment with myelodysplastic syndrome the patient pop. doubles again.
Thanks a million for your perspective. My highly biased take on it is that they are about to get that compelling evidence. It may be only 50 patients deep but it will be hard to ignore over 70 percent being salvaged for even a few monts even before accounting for the 45 percent CRs. 50 patients is enough to see a signature for toxicity if one was present even before considering that SGN technology primacy is totally hinged on manageable toxicity. Mgt has been very giddy on 33A and BB have been putting a lot of their money where their informed thought is so I'm feeling pretty good about being insanely overinvested in SGEN right now.
Really appreciate your insignts especially when they run along side mybown ;-).
No problem Kool. I really don't know much about the FDA granting accelerated approval. My guess is they would be somewhat leery granting approval too quickly after Mylotarg was approved for AML and then subsequently had to be withdrawn due to excessive toxicity without much in the way of increased survival. My guess is they would have to see some very compelling PFS or OS from SGN 33A to move up any timelines. Due to the highly aggressive nature of AML , especially in the advanced age group, it probably won't take as long to generate that important survival data.
Thanks for sharing your diligence Atpl. Question in my mind is if this limited data could be used by the FDA to grant conditional approval at least for salvage situations until the P3 concludes years from now because of the obvious unmet medical need for dealing with this disease. Given the dearth of alternatives for a very grim prognosis, is there not an ethical issue for the FDA to ponder?
TIA for adding any explanations, clarifications and/or opinions.
I had EXEL from 1.30 along with ISR. I have a bunch of BB choices like NVTA, SGEN in my holdings. I should have held EXEL longer!
Sentiment: Strong Buy